2021-11-05T00:31:40-05:00 2020-12-31 861065772 DELOITTE TAX LLP 50 SOUTH SIXTH STREET MINNEAPOLIS MN 55402 990 2020-01-01 821808476 BILL & MELINDA GATES MEDICAL RESEARCH INSTITUTE BILL 8577022108 ONE KENDALL SQ BLDG 600 NO 6-301 CAMBRIDGE MA 02139 MAHENDRA PATTNI TREASURER 8577022108 2021-11-04 1 MAHENDRA PATTNI 999009999 ANNE FULTON P00941863 6123974000 3 AAL1 IAL1 2020 2022-09-23 18:48:47Z PENNY M HEATON ONE KENDALL SQ BLDG 600 NO 6-301 CAMBRIDGE MA 02139 32100737 0 X WWW.GATESMRI.ORG X 2017 WA THE GATES MRI ACTIVELY AND CONTINUOUSLY ENGAGES DIRECTLY IN THE CONDUCT OF MEDICAL RESEARCH IN CONJUNCTION WITH ONE OR MORE HOSPITALS FOR THE PURPOSE OF ADDRESSING MAJOR CAUSES OF ILLNESS AND DEATH IN LOW-INCOME COUNTRIES. 5 0 100 0 0 0 9254862 31990419 0 0 545619 110318 7383 0 9807864 32100737 0 0 0 0 24217965 30689083 0 0 0 17009587 68682231 41227552 99371314 -31419688 -67270577 219318998 171367184 3618596 22937359 215700402 148429825 X THE GATES MRI ACTIVELY AND CONTINUOUSLY ENGAGES DIRECTLY IN THE CONDUCT OF MEDICAL RESEARCH IN CONJUNCTION WITH ONE OR MORE HOSPITALS FOR THE PURPOSE OF ADDRESSING MAJOR CAUSES OF ILLNESS AND DEATH IN LOW-INCOME COUNTRIES. 0 0 69907671 BILL & MELINDA GATES MEDICAL RESEARCH INSTITUTE ("GATES MRI") IS ALIGNED WITH THE PURPOSE OF THE BILL & MELINDA GATES FOUNDATION AND GUIDED BY THE VISION THAT EVERY PERSON DESERVES THE OPPORTUNITY TO LEAD A HEALTHY AND PRODUCTIVE LIFE. THE GATES MRI ACTIVELY AND CONTINUOUSLY ENGAGES DIRECTLY IN MEDICAL RESEARCH IN CONJUNCTION WITH ONE OR MORE HOSPITALS FOR THE PURPOSE OF ADDRESSING MAJOR CAUSES OF ILLNESS AND DEATH IN LOW-AND MIDDLE-INCOME COUNTRIES. THE GATES MRI WORKS TO CAPITALIZE ON INNOVATIONS IN MEDICAL RESEARCH, EMPLOYING RIGOROUS APPROACHES TO RESEARCH AND DEVELOPMENT, TO IDENTIFY PHARMACEUTICAL PRODUCT CANDIDATES THAT ADDRESS DISEASES DISPROPORTIONATELY BURDENING THE WORLD'S POOREST REGIONS. THE GATES MRI'S CURRENT PORTFOLIO IS ALIGNED WITH GLOBAL PRIORITIES TO ERADICATE MALARIA, ACCELERATE THE END OF THE TUBERCULOSIS EPIDEMIC, END DIARRHEAL DEATHS IN CHILDREN AND FIGHT SERIOUS DISORDERS AFFECTING MATERNAL AND NEWBORN CHILD HEALTH. 16977555 IN RESPONSE TO THE GLOBAL OUTBREAK OF COVID-19 IN 2020, THE GATES MRI CONDUCTED A CLINICAL STUDY TO RECRUIT PATIENTS WITH MILD COVID-19 EARLY AFTER SYMPTOMS ONSET TO TEST POTENTIAL THERAPEUTICS TO TREAT COVID-19. THIS STUDY WAS FUNDED BY GRANTS FROM THE BILL & MELINDA GATES FOUNDATION AND GATES PHILANTHROPY PARTNERS. 86885226 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 1 38 0 1 100 1 0 0 0 0 0 0 0 0 0 0 0 0 X 5 0 1 0 0 0 1 1 1 1 1 1 0 1 1 1 1 1 1 1 1 0 MA WA X X JENNIFER DEGER 2067093100 500 FIFTH AVENUE N SEATTLE WA 98109 TREVOR MUNDEL DIRECTOR, BOARD CHAIR 3.00 40.00 X 0 1137035 80764 CAROLYN AINSLIE START 432020 DIRECTOR 2.00 40.00 X 0 762493 80403 HELENE MADONICK DIRECTOR 2.00 40.00 X 0 680655 52814 EMILIO EMINI DIRECTOR 2.00 40.00 X 0 559237 67297 SUSAN DESMOND-HELLMANN DIRECTOR 2.00 41.00 X 0 339358 39651 ANDREW FARNUM END 432020 DIRECTOR 2.00 40.00 X 0 118416 22461 PENNY HEATON CHIEF EXECUTIVE OFFICER 40.00 0.00 X 805524 0 69399 MARY THISTLE TREASURER 40.00 0.00 X 449600 0 67790 SALLY JENNINGS SECRETARY 40.00 0.00 X 413402 0 79597 JARED SILVERMAN HEAD OF TRANSLATIONAL DISCOV 40.00 0.00 X 447904 0 81892 DEBRA WEISS HEAD OF QUAL ASSUR AND OPS 40.00 0.00 X 447568 0 66652 JORG THOMMES HEAD OF CHEM, MANU, CONTROLS 40.00 0.00 X 430862 0 79229 DAVID KAUFMAN END 2122020 HEAD OF TRANSLATIONAL DEVELOPMENT 40.00 0.00 X 418457 0 70671 DINA BERDIEVA END 12042020 HEAD OF PRJ MGMT, CLINICAL OPS 40.00 0.00 X 387641 0 283949 MONICAH OTIENO HEAD OF NONCLINICAL DEVELOP 40.00 0.00 X 493061 0 77608 ALEXANDER SCHMIDT HEAD OF VACCINE DEVELOPMENT 40.00 0.00 X 431488 0 79695 TARYN ROGALSKI-SALTER HEAD OF GLOBAL REG STRATEGY 40.00 0.00 X 436655 0 70479 JINTANAT ANANWORANICH CLINICAL DEVELOPMENT LEADER 40.00 0.00 X 412788 0 79431 CHARLES WELLS HEAD OF THERAPEUTICS DEVELOPMENT 40.00 0.00 X 450447 0 67766 6025397 3597194 1517548 85 0 1 0 MMS HOLDING INC 6880 COMMERCE BLVD CANTON MI 48187 CLINICAL DATA MANAGEMENT SERVICES 2732869 IQVIA RDS INC 4820 EMPEROR BLVD DURHAM NC 27703 CLINICAL RESEARCH ORGANIZATION 2326891 LOGIX INC 1601 TRAPELO ROAD SUITE 230 WALTHAM MA 02451 SUPPLEMENTAL STAFFING & CONSULTING SERV 1555322 PPD DEVELOPMENT LP 929 NORTH FRONT STREET WILMINGTON NC 28401 CLINICAL RESEARCH ORGANIZATION 1218389 LATHAM BIOPHARM GROUP INC 101 MAIN STREET SUITE 1400 CAMBRI CAMBRIDGE MA 02142 SUPPLEMENTAL STAFFING & CONSULTING SERV 1191505 41 31209732 780687 31990419 110318 110318 32100737 0 0 110318 X 4401215 2494684 1906531 19441624 15109119 4332505 2523366 1961042 562324 3123417 2197868 925549 1199461 947195 252266 1743729 1586314 157415 226515 226515 46952320 45131654 1820666 1974 1974 391887 278111 113776 1156170 1028468 127702 10000000 10000000 5668046 4266473 1401573 268699 228159 40540 47712 14737 32975 606185 456290 149895 140910 63914 76996 FURNITURE AND EQUIPMENT 1285842 959872 325970 DUES AND SUBSCRIPTIONS 147773 128051 19722 OTHER TAXES AND FEES 25898 25083 815 RECRUITING 10033 8192 1841 8538 8538 99371314 86885226 12486088 0 30229648 42576143 184053647 108703803 46088 307534 2098774 4119401 16149664 613217 2386309 15536447 504532 123856 219318998 171367184 3618596 22937359 3618596 22937359 X 215700402 145367616 3062209 215700402 148429825 219318998 171367184 -67270577 0 X 0 1 X 1 0 X UNIVERSITY OF WASHINGTON SEATTLE WA RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 15265719 550116 14715603 875729 62188 813541 8216 913 7303 15536447 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES CONDUCT MEDICAL RESEARCH, IDENTIFY MEDICAL RESEARCH PARTNERS 1942 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 PROGRAM SERVICES CONDUCT MEDICAL RESEARCH, IDENTIFY MEDICAL RESEARCH PARTNERS 1586870 NORTH AMERICA 0 0 PROGRAM SERVICES CONDUCT MEDICAL RESEARCH, IDENTIFY MEDICAL RESEARCH PARTNERS 172 SOUTH ASIA 0 0 PROGRAM SERVICES CONDUCT MEDICAL RESEARCH, IDENTIFY MEDICAL RESEARCH PARTNERS 6693 MIDDLE EAST AND NORTH AFRICA 0 0 PROGRAM SERVICES CONDUCT MEDICAL RESEARCH, IDENTIFY MEDICAL RESEARCH PARTNERS 242 SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICES CONDUCT MEDICAL RESEARCH, IDENTIFY MEDICAL RESEARCH PARTNERS 1454791 SOUTH AMERICA 0 0 PROGRAM SERVICES CONDUCT MEDICAL RESEARCH, IDENTIFY MEDICAL RESEARCH PARTNERS 4671 0 0 0 0 0 0 3055381 0 3055381 1 0 0 0 0 0 PART III ACCOUNTING METHOD: SCHEDULE F, PART VI, LINE1: THERE WERE TRANSFERS OF CASH TO FOREIGN CORPORATIONS BUT THEY WERE NOT OF THE TYPE DESCRIBED IN SECTION 6038B(A)(1)(A), 367(D), OR 367(E) SO NO FORM 926 WAS REQUIRED TO BE FILED. X X 1 1 X X X 1 0 0 0 0 0 0 1 0 TREVOR MUNDEL DIRECTOR, BOARD CHAIR 0 1074457 0 3500 0 59078 0 42750 0 38014 0 1217799 0 0 PENNY HEATON CHIEF EXECUTIVE OFFICER 758459 0 3000 0 44065 0 42750 0 26649 0 874923 0 0 0 CAROLYN AINSLIE START 432020 DIRECTOR 0 716028 0 3500 0 42965 0 42750 0 37653 0 842896 0 0 HELENE MADONICK DIRECTOR 0 198720 0 30422 0 451513 0 37296 0 15518 0 733469 0 0 DINA BERDIEVA END 12042020 HEAD OF PRJ MGMT, CLINICAL OPS 385358 0 1500 0 783 0 241669 0 42280 0 671590 0 0 0 EMILIO EMINI DIRECTOR 0 533008 0 2000 0 24229 0 42750 0 24547 0 626534 0 0 MONICAH OTIENO HEAD OF NONCLINICAL DEVELOP 338385 0 78180 0 76496 0 42750 0 34858 0 570669 0 0 0 JARED SILVERMAN HEAD OF TRANSLATIONAL DISCOV 433308 0 3665 0 10931 0 42750 0 39142 0 529796 0 0 0 CHARLES WELLS HEAD OF THERAPEUTICS DEVELOPMENT 406994 0 13556 0 29897 0 42750 0 25016 0 518213 0 0 0 MARY THISTLE TREASURER 419159 0 13000 0 17441 0 42750 0 25040 0 517390 0 0 0 DEBRA WEISS HEAD OF QUAL ASSUR AND OPS 425073 0 13500 0 8995 0 42750 0 23902 0 514220 0 0 0 ALEXANDER SCHMIDT HEAD OF VACCINE DEVELOPMENT 408311 0 13882 0 9295 0 42750 0 36945 0 511183 0 0 0 JORG THOMMES HEAD OF CHEM, MANU, CONTROLS 413735 0 3500 0 13627 0 42750 0 36479 0 510091 0 0 0 TARYN ROGALSKI-SALTER HEAD OF GLOBAL REG STRATEGY 403385 0 8180 0 25090 0 42750 0 27729 0 507134 0 0 0 SALLY JENNINGS SECRETARY 392039 0 8673 0 12690 0 42750 0 36847 0 492999 0 0 0 JINTANAT ANANWORANICH CLINICAL DEVELOPMENT LEADER 345364 0 9123 0 58301 0 42750 0 36681 0 492219 0 0 0 DAVID KAUFMAN END 2122020 HEAD OF TRANSLATIONAL DEVELOPMENT 408944 0 1500 0 8013 0 42750 0 27921 0 489128 0 0 0 SUSAN DESMOND-HELLMANN DIRECTOR 0 218476 0 0 0 120882 0 34019 0 5632 0 379009 0 0 PART I, LINE 1A THE TRAVEL POLICY, APPLICABLE TO ALL EMPLOYEES, ALLOWS FOR FIRST-CLASS AIR TRAVEL ON DOMESTIC RED-EYE FLIGHTS DEPARTING AFTER 9:00 PM THAT EXCEED FIVE HOURS IN DURATION. RELOCATION PACKAGES ARE GENERALLY PROVIDED TO NEW EMPLOYEES WHO RESIDE MORE THAN 50 MILES OUTSIDE OF CAMBRIDGE, MASSACHUSSETTS. THE ORGANIZATION GROSSES UP TAXABLE RELOCATION BENEFITS. PART I, LINE 4A: HELENE MADONICK $411,468 PART I, LINE 7: ALL EMPLOYEES ARE ELIGIBLE TO RECEIVE HIGH IMPACT BONUSES, ANNUALLY. THESE BONUSES ARE DISCRETIONARY TO BE PAID BASED ON PREDETERMINED FIXED AMOUNTS (BETWEEN $2,500 AND $10,000) AND THE TOTAL AMOUNT PAID IS DETERMINED BASED ON PERFORMANCE AND THE IMPACT ON THE ORGANIZATION. DURING 2020, GATES MEDICAL RESEARCH INSTITUTE PAID OUT HIGH IMPACT BONUSES, INCLUDING TO INDIVIDUALS LISTED ON PART VII, SECTION A. PART VII, SECTION A, LINE 1: TOTAL ANNUAL COMPENSATION IS REPORTED FOR ALL DIRECTORS, OFFICERS AND KEY EMPLOYEES REGARDLESS OF THE LENGTH OF TIME ACTIVELY SERVING AS A DIRECTOR, OFFICER, OR KEY EMPLOYEE OF GATES MEDICAL RESEARCH INSTITUTE DURING 2020. FORM 990, PART VI, SECTION A, LINE 2 SUSAN DESMOND-HELLMANN, CAROLYN AINSLIE, TREVOR MUNDEL, ANDREW FARNUM, EMILIO EMINI, AND HELENE MADONICK HAVE A BUSINESS RELATIONSHIP AS EMPLOYEES OF THE BILL & MELINDA GATES FOUNDATION. FORM 990, PART VI, SECTION A, LINE 6 THE SOLE MEMBER OF BILL & MELINDA GATES MEDICAL RESEARCH INSTITUTE IS BILL & MELINDA GATES FOUNDATION. FORM 990, PART VI, SECTION A, LINE 7A BILL & MELINDA GATES FOUNDATION, THE SOLE MEMBER OF BILL & MELINDA GATES MEDICAL RESEARCH INSTITUTE, HAS THE AUTHORITY TO APPOINT AND REMOVE DIRECTORS. FORM 990, PART VI, SECTION A, LINE 7B BILL & MELINDA GATES FOUNDATION, THE SOLE MEMBER OF BILL & MELINDA GATES MEDICAL RESEARCH INSTITUTE, HAS THE AUTHORITY TO AMEND THE ARTICLES OF INCORPORATION, ADOPT A PLAN OF MERGER OR CONSOLIDATION, AUTHORIZE THE SALE, LEASE, OR EXCHANGE OF ALL OR SUBSTANTIALLY ALL OF THE ASSETS OF THE ORGANIZATION, AUTHORIZE THE VOLUNTARY DISSOLUTION OF THE ORGANIZATION AND ADOPTION OF A PLAN FOR THE DISTRIBUTION OF THE ASSETS OF THE ORGANIZATION, IN ACCORDANCE WITH THE ORGANIZATION'S ORGANIZATIONAL DOCUMENTS. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS PREPARED BY A THIRD-PARTY ACCOUNTANT. AFTER PREPARATION, IT IS REVIEWED IN DETAIL BY THE TREASURER OF THE INSTITUTE, AND THE TAX TEAM AND CONTROLLER OF BILL & MELINDA GATES FOUNDATION, THE SOLE MEMBER OF BILL & MELINDA GATES MEDICAL RESEARCH INSTITUTE. A COPY OF THE FORM 990 IS PROVIDED TO THE ENTIRE BOARD PRIOR TO FILING WITH THE INTERNAL REVENUE SERVICE. FORM 990, PART VI, SECTION B, LINE 12C ALL OFFICERS, DIRECTORS AND KEY EMPLOYEES ARE CONSIDERED "COVERED PERSONS" FOR THE ORGANIZATION'S CONFLICT OF INTEREST POLICY, AND AS SUCH, ARE REQUIRED TO ANNUALLY DISCLOSE ANY RELATIONSHIPS THAT COULD GIVE RISE TO CONFLICTS OF INTEREST INVOLVING THE ORGANIZATION. IN ADDITION, ANY TRANSACTIONS BETWEEN THE ORGANIZATION AND ANY OF THESE INDIVIDUALS (OR THEIR FAMILY MEMBERS OR AN AFFILIATED ENTITY) MUST BE DISCLOSED TO THE SECRETARY. IF THE SECRETARY HAS A POTENTIAL CONFLICT OF INTEREST, IT MUST BE DISCLOSED TO THE CHIEF EXECUTIVE OFFICER. THE SECRETARY AND CHIEF EXECUTIVE OFFICER ARE RESPONSIBLE FOR REVIEWING THE ANNUAL CONFLICT OF INTEREST DISCLOSURES AND RESOLVING ANY POTENTIAL CONFLICT OF INTERESTS THAT MAY ARISE. THE COVERED PERSON IS REQUIRED TO REFRAIN FROM USING HIS OR HER PERSONAL INFLUENCE TO ENCOURAGE THE ORGANIZATION TO ENTER INTO THE COVERED TRANSACTION. ADDITIONALLY, HE OR SHE MUST NOT PARTICIPATE IN ANY DISCUSSIONS REGARDING THE COVERED TRANSACTIONS WITH OFFICERS, DIRECTORS AND EMPLOYEES OF THE ORGANIZATION, EXCEPT TO RESPOND TO REQUESTS FOR INFORMATION. IF THE TRANSACTION IS DEEMED TO BE REASONABLE BY THE DISINTERESTED DIRECTORS (IN THE CASE OF A CONFLICT INVOLVING A DIRECTOR OR THE CHIEF EXECUTIVE OFFICER) OR CHIEF EXECUTIVE OFFICER (IN THE CASE OF A CONFLICT INVOLVING ANOTHER OFFICER OR KEY EMPLOYEE), THE ORGANIZATION MAY ENTER INTO THE TRANSACTION, AS LONG AS IT IS FAIR AND REASONABLE TO THE ORGANIZATION. SIMILAR TO THE COVERED PERSONS, ALL EMPLOYEES ARE REQUIRED TO COMPLETE A CONFLICT OF INTEREST CERTIFICATION UPON COMMENCING EMPLOYMENT AND TO UPDATE THE CERTIFICATION ANNUALLY, AND AT ANY TIME THERE IS A CHANGE THAT REQUIRES DISCLOSURE. THE HEAD OF COMPLIANCE & RISK MANAGEMENT IS RESPONSIBLE FOR REVIEWING THE CERTIFICATIONS AND ADMINISTERING AND MAINTAINING THE POLICY. THE POLICY RETAINS THAT IF AN OFFICER, DIRECTOR, OR MEMBER OF SENIOR LEADERSHIP BECOMES AWARE OF A TRANSACTION THAT COULD CAUSE A CONFLICT OF INTEREST, THEY ARE TO IMMEDIATELY DISCLOSE SUCH TO THE SECRETARY OF THE ORGANIZATION. PROCEDURES FOR RESOLVING A COVERED TRANSACTION AFTER DISCLOSURE TO THE SECRETARY REMAIN IN PLACE AS OUTLINED ABOVE. FORM 990, PART VI, SECTION B, LINE 15 THE BOARD OF THE BILL & MELINDA GATES MEDICAL RESEARCH INSTITUTE USES AN INDEPENDENT REVIEW, COMPARABILITY DATA AND CONTEMPORANEOUS SUBSTANTIATION TO ESTABLISH TOTAL REMUNERATION PACKAGES FOR THE CEO, OFFICERS, AND CERTAIN KEY EMPLOYEES. THE BOARD IS PRESENTED WITH STUDY DATA, REVIEWS IT TO DETERMINE REASONABLENESS, AND THEN APPROVES TOTAL REMUNERATION ACCORDINGLY. ALL SUCH OFFICER AND CERTAIN KEY EMPLOYEE TOTAL REMUNERATION PACKAGES ARE REVIEWED AND APPROVED BY THE BOARD ANNUALLY. THE MOST RECENT COMPENSATION STUDY FOR PURPOSES OF THIS COMPENSATION PERIOD WAS CONDUCTED BY AN INDEPENDENT CONSULTANT IN 2020. COMPARABILITY DATA IS ALSO USED TO ESTABLISH COMPENSATION PACKAGES FOR OTHER EMPLOYEES. COMPENSATION PACKAGES FOR OTHER EMPLOYEES ARE APPROVED BY THE CEO ANNUALLY, BASED ON A COMPENSATION PHILOSOPHY ORIGINALLY APPROVED BY THE BOARD. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY ARE AVAILABLE UPON REQUEST. BILL & MELINDA GATES MEDICAL RESEARCH INSTITUTE'S FINANCIAL STATEMENTS ARE CONSOLIDATED WITH BILL & MELINDA GATES FOUNDATION, AND THE CONSOLIDATED FINANCIAL STATEMENTS ARE AVAILABLE AT WWW.GATESFOUNDATION.ORG. FORM 990, PART IX, LINE 11G OTHER FEES FOR SERVICES: PROGRAM SERVICE EXPENSES 13,036,360. MANAGEMENT AND GENERAL EXPENSES 62,400. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 13,098,760. SCIENTIFIC CONSULTING AND TECHNICAL ASSISTANCE: PROGRAM SERVICE EXPENSES 31,396,148. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 31,396,148. RECRUITING AND PUBLIC RELATIONS: PROGRAM SERVICE EXPENSES 668,854. MANAGEMENT AND GENERAL EXPENSES 72,606. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 741,460. OPERATIONAL ASSISTANCE: PROGRAM SERVICE EXPENSES 30,292. MANAGEMENT AND GENERAL EXPENSES 1,685,660. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 1,715,952. FORM 990, PART VI, SECTION A, LINE 9: ANY OFFICER, DIRECTOR, TRUSTEE, OR KEY EMPLOYEE THAT IS OR WAS AN EMPLOYEE OF THE BILL & MELINDA GATES FOUNDATION CAN BE REACHED AT THE FOLLOWING ADDRESS. FOR 2020, THIS INCLUDES SUSAN DESMOND-HELLMANN, CAROLYN AINSLIE, TREVOR MUNDEL, EMILIO EMINI, HELENE MADONICK AND ANDREW FARNUM: P.O. BOX 23350 SEATTLE, WA 98102 FORM 990, PART VII, SECTION A: SUSAN DESMOND-HELLMANN RECEIVED COMPENSATION FROM BILL & MELINDA GATES FOUNDATION (BMGF) IN HER CAPACITY AS THE CEO THROUGH JANUARY 31, 2020. THE RELATED ORGANIZATION HOURS REFLECTED IN PART VII, COLUMN B REPRESENT 40 AVERAGE HOURS PER WEEK AT BMGF AND 1 AVERAGE HOUR PER WEEK AS DIRECTOR OF GATES PHILANTHROPY PARTNERS THROUGH JANUARY 31, 2020. BILL & MELINDA GATES FOUNDATION (BMGF) PO BOX 23350 SEATTLE WA 98102 562618866 GRANTMAKING FOUNDATION WA 501(C)(3) PF N/A 0 GATES PHILANTHROPY PARTNERS PO BOX 23350 SEATTLE WA 98102 473290897 GRANTMAKING PUBLIC CHARITY WA 501(C)(3) LINE 7 BILL & MELINDA GATES FOUNDATION (BMGF) 1 BILL & MELINDA GATES FOUNDATION TRUST (BMGFT) PO BOX 23350 SEATTLE WA 98102 911663695 GRANTMAKING FOUNDATION WA 501(C)(3) PF N/A 0 ACCELERATOR GPS SIDE CAR FUND LP PO BOX 13329 RESEARCH TRIANGLE PARK NC 27709 814667411 PROGRAM RELATED INVESTMENT OF BMGF DE N/A 0 0 GREENBRIAR AS HOLDINGS LP 555 THEODORE FREMD AVE STE A-201 RYE NY 10580 981208908 INVESTMENT OF BMGFT CJ N/A 0 0 GREENBRIAR EQUITY FUND III AIV MM NV LP 555 THEODORE FREMD AVE STE A-201 RYE NY 10580 811112433 INVESTMENT OF BMGFT DE N/A 0 0 GREENBRIAR EQUITY FUND III AIV NV LP 555 THEODORE FREMD AVE STE A-201 RYE NY 10580 981208417 INVESTMENT OF BMGFT CJ N/A 0 0 GREENBRIAR EQUITY FUND III AIV SK NV LP 555 THEODORE FREMD AVE STE A-201 RYE NY 10580 473805287 INVESTMENT OF BMGFT DE N/A 0 0 GREENBRIAR EQUITY FUND III-A AIV WFCI LP 555 THEODORE FREMD AVE STE A-201 RYE NY 10580 981219020 INVESTMENT OF BMGFT CJ N/A 0 0 GREENBRIAR EQUITY FUND III-A LP 555 THEODORE FREMD AVE STE A-201 RYE NY 10580 461543216 INVESTMENT OF BMGFT DE N/A 0 0 THE GLOBAL GOOD FUND I LLC 3150 139TH AVE SE BELLEVUE WA 98005 272796838 INVESTMENT OF BMGFT DE N/A 0 0 AFRICAN AGRICULTURAL CAPITAL FUND LLC 6TH FLOOR TOWER A 1 CYBERCITY EBENE MP 981017696 PROGRAM RELATED INVESTMENT OF BMGF MP N/A C 1 GREENBRIAR AS LP 555 THEODORE FREMD AVE STE A-201 RYE NY 10580 981208754 INVESTMENT OF BMGFT CJ N/A C 0 0 0 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 GATES PHILANTHROPY PARTNERS C 18000000 CASH GRANT FOR COVID-19 RESPONSE